title: [Update on Current Care Guideline: Parkinson's disease].
abstract: The treatment of Parkinson's disease may be initiated with dopamine agonist or MAO-B-inhibitor for people under 60-65 years of age. For older patients, the treatment may also be started with levodopa. If there are motor complications, such as on-off-symptoms, apomorphin injections can be beneficial in addition to other medications. In the case of difficult on-off-symptoms and dyskinesias in spite of optimal treatment, deep brain stimulation, duodenal levodopa infusion and apomorphine infusion should be considered. Rehabilitation can improve gait speed and balance, decrease falls and improve speech. However, with advancing disease the results are not maintained if trainino is discontinued.
authors.forename: Eero
authors.initials: E
authors.lastname: Pekkonen
authors.forename: Sari
authors.initials: S
authors.lastname: Atula
authors.forename: Jaana
authors.initials: J
authors.lastname: Autere
authors.forename: Johanna
authors.initials: J
authors.lastname: Eerola-Rautio
authors.forename: Valtteri
authors.initials: V
authors.lastname: Kaasinen
authors.forename: Mikko
authors.initials: M
authors.lastname: Kauppinen
authors.forename: Kirsti
authors.initials: K
authors.lastname: Martikainen
authors.forename: Hanna
authors.initials: H
authors.lastname: Ruottinen
authors.forename: Meri
authors.initials: M
authors.lastname: Viljamaa
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001058:Apomorphine / Q000627:therapeutic use; D046690:Deep Brain Stimulation; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000628:therapy*; D017410:Practice Guidelines as Topic
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa; D001058:Apomorphine